Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 2, 2026
Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Actinium Pharmaceuticals (NYSE:ATNM)Defense World · Oct 2, 2026
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Recommendation of “Moderate Buy” by BrokeragesDefense World · Sep 21, 2026
Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)Seeking Alpha · Sep 12, 2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Sep 3, 2026
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Buy” from BrokeragesDefense World · Aug 27, 2026Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$3.67 | -$2.87 | Beat |
| May 7, 2026 | -$3.58 | -$3.20 | Beat |
| Feb 19, 2026 | -$3.13 | -$3.50 | Miss |
| Nov 5, 2025 | -$3.45 | -$3.36 | Beat |
| Aug 4, 2025 | -$3.40 | -$3.31 | Beat |
| May 2, 2025 | -$3.20 | -$3.29 | Miss |